New research in Science found that losing 10% of body weight through GLP-1 therapy restored near-normal heart muscle function in patients with obesity-related heart failure.
For years, the medical community has understood that obesity strains the heart. What has been less clear is whether that strain can be undone. A study published in Science offers some of the most specific evidence yet that it can, at least for a particular and surprisingly common form of heart failure.
The research focused on heart failure with preserved ejection fraction, known as HFpEF, a condition in which the heart pumps blood at a normal rate but cannot fill properly because the muscle has stiffened. It accounts for roughly half of all heart failure cases and is significantly more prevalent among people with obesity. Despite how common it is, treatment options have historically been limited.
What the study found
Researchers examined heart muscle cells from 80 patients and divided them into two groups based on body mass index. Those who reduced their BMI by more than 2 kg/m² through treatment showed measurable improvements in how forcefully their heart muscle cells contracted. Among a subset of patients who lost at least 10% of their body weight over roughly 18 months using GLP-1 receptor agonists, the improvements were more pronounced. Their heart muscle contraction ability recovered to near-normal levels.
The treatment in question involves injectable GLP-1 receptor agonists, a class of drugs originally developed for type 2 diabetes that has gained significant attention for its effectiveness in treating obesity.
The protein at the center of the damage
The study identified a specific mechanism driving the dysfunction. A protein called troponin-I, which regulates how muscle fibers contract and relax, showed elevated phosphorylation in patients with severe obesity and HFpEF. That elevated phosphorylation was found to weaken the force generated by heart muscle cells. Weight loss appeared to reverse those changes, restoring the protein’s normal behavior and, with it, the muscle’s capacity to contract effectively.
This is meaningful because it moves the conversation from correlation to mechanism. The research does not just confirm that weight loss is associated with better cardiac outcomes. It identifies a specific molecular pathway through which the damage occurs and through which recovery appears to happen.
How common is this, and who is most affected
Obesity has more than doubled globally since 1990. At least 16% of adults worldwide are currently classified as obese, and the cardiovascular consequences of that trend are well-documented. Obesity roughly doubles the risk of developing heart failure overall.
Dr. Naveed Sattar of the University of Glasgow noted that while the connection between severe obesity and HFpEF is firmly established, only about 5% of people with severe obesity in the United States develop this specific form of heart failure. That figure provides important context. The findings are significant, but they apply to a defined population rather than everyone with obesity.
Dr. David Kass of Johns Hopkins University has pointed to the need for continued research into the biological changes that accompany GLP-1 treatment, since the drugs’ cardiac effects may extend beyond what weight loss alone explains.
Obesity’s reach beyond the heart
The cardiac findings arrive alongside separate research presented at the American Physiology Summit, which found that older adults with obesity show substantially reduced lung capacity. That reduction contributes to chronic shortness of breath and other respiratory complications, reinforcing that obesity operates across multiple organ systems simultaneously. Managing it effectively requires approaches that account for that breadth.
The Science study adds a concrete biological target to those efforts. Identifying troponin-I phosphorylation as a reversible driver of cardiac dysfunction gives researchers and clinicians something specific to track, treat and potentially intervene on before heart failure becomes the outcome.
